Clinical EfficacyMost patients maintained their response after six months off-treatment from batoclimab, and nearly half of responders achieved ATD-free remission, providing evidence of significant clinical benefit.
Drug DevelopmentThe likelihood of success in Phase 3 is considered greater given the trials were optimized with batoclimab's Phase 2 experience in mind, and patients are receiving higher doses with IMVT-1402.
Market PotentialMaintaining a Buy rating and a price objective of $30 based on valuation and peak sales opportunity for IMVT’s FcRn programs.